Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing its multiple sclerosis therapy candidate, LUCID-MS, into Phase 2 clinical development after Phase 1 studies demonstrated a favorable safety profile. The therapy, designed to target demyelination and protect or restore myelin integrity, was generally well tolerated in healthy volunteers, supporting progression to patient-focused studies.
In April 2026, the company submitted an Investigational New Drug application to the U.S. Food and Drug Administration for LUCID-MS, clearing the path for a planned Phase 2 clinical trial in people living with multiple sclerosis. Quantum BioPharma believes the therapy may offer a differentiated, potentially first-in-class approach because it aims to directly address myelin loss and neurodegeneration, rather than relying solely on immune modulation. The company is also strengthening operational support for the program through a planned partnership with Allucent and engagement with neurological specialists.
The full article detailing these developments can be accessed at https://ibn.fm/AUhNl.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is focused on the research and development of LUCID-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models.
The company also invented unbuzzd and spun out its OTC version to Unbuzzd Wellness Inc., led by industry veterans. Quantum BioPharma retains ownership of 19.84% of UWI and is entitled to royalty payments of 7% of sales from unbuzzd until payments total $250 million, after which the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations for pharmaceutical and medical uses.
Latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM.
